Oliver R Sum-Ping, MD
Sleep Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sum-Ping’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A136548 · Current
Licensed to practise in California · since 2015 · expires 2027-02-28 · University of Texas Southwestern Medical School at Dallas.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$42,952
Medicare paid this office $42,952 for 358 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Sleep study in sleep lab (6 years or older) | 96 | $9,911 | $102 |
| Return visit (30+ min) | 99 | $8,742 | $82 |
| New patient visit (45+ min) | 89 | $8,659 | $97 |
| Long return visit (40+ min) | 27 | $4,683 | $142 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 35 | $3,918 | $106 |
See all 8 services
| Sleep study in sleep lab (6 years or older) | 96 | $9,911 | $102 |
| Return visit (30+ min) | 99 | $8,742 | $82 |
| New patient visit (45+ min) | 89 | $8,659 | $97 |
| Long return visit (40+ min) | 27 | $4,683 | $142 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 35 | $3,918 | $106 |
| Short return visit (20+ min) | 50 | $3,358 | $65 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 104 | $1,558 | $15 |
| Sleep study including heart rate, breathing, and sleep time | 40 | $1,396 | $35 |
Who their Medicare patients are
358 Original Medicare patients in 2024. Average age 71 · Under 65 12% · 85 and older 7% · Women 49% · Also on Medicaid 17% · Health risk score 1.16. At or below the middle of the specialty; the typical sleep medicine clinician is at 1.21.
Conditions among them: High blood pressure 65% · Diabetes 27% · Coronary heart disease 25% · Depression 25% · Atrial fibrillation 22% · Chronic kidney disease 18% · Cancer 16% · Heart failure 14% · Stroke 10% · COPD 7% · Dementia 7%.
The office billed $362,328, Medicare allowed $58,716 and paid $42,952; for 572 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 358 | 572 | 71 | 1.16 | $362,328 | $42,952 |
| 2023 | 429 | 567 | 71 | 1.17 | $307,007 | $51,324 |
| 2022 | 476 | 619 | 71 | 1.28 | $351,029 | $57,277 |
| 2021 | 381 | 499 | 71 | 1.24 | $316,571 | $46,180 |
| 2020 | 392 | 534 | 70 | 1.36 | $271,647 | $33,967 |
| 2019 | 115 | 127 | 70 | 1.15 | $44,644 | $11,815 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 169 | $14,383 | $82 |
| New patient visit (45+ min) | 126 | $14,314 | $114 |
| Sleep study in sleep lab (6 years or older) | 79 | $8,456 | $104 |
| Long return visit (40+ min) | 33 | $4,444 | $120 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 36 | $3,580 | $99 |
| Short return visit (20+ min) | 45 | $2,881 | $60 |
| Sleep study including heart rate, breathing, and sleep time | 40 | $1,398 | $35 |
2022: 8 services
| Return visit (30+ min) | 201 | $17,487 | $84 |
| New patient visit (45+ min) | 125 | $13,813 | $111 |
| Sleep study in sleep lab (6 years or older) | 79 | $8,181 | $101 |
| Long return visit (40+ min) | 36 | $5,613 | $125 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 47 | $5,349 | $111 |
| New patient visit (60+ min) | 20 | $2,970 | $148 |
| Sleep study including heart rate, breathing, and sleep time | 45 | $1,542 | $34 |
| Short return visit (20+ min) | 18 | $895 | $50 |
2021: 10 services
| Return visit (30+ min) | 168 | $14,647 | $83 |
| New patient visit (45+ min) | 106 | $11,722 | $111 |
| Sleep study in sleep lab (6 years or older) | 56 | $5,909 | $102 |
| Long return visit (40+ min) | 21 | $3,655 | $126 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 26 | $2,916 | $112 |
| New patient visit (60+ min) | 15 | $2,337 | $156 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,711 | $90 |
| Sleep study including heart rate, breathing, and sleep time | 35 | $1,315 | $38 |
| Short return visit (20+ min) | 17 | $1,028 | $60 |
| New patient visit (30+ min) | 13 | $747 | $57 |
2020: 13 services
| Sleep study in sleep lab (6 years or older) | 65 | $6,791 | $104 |
| Short return visit (20+ min) | 126 | $5,525 | $41 |
| Extended patient service without direct patient contact, first hour | 48 | $4,797 | $100 |
| New patient visit (60+ min) | 35 | $3,383 | $97 |
| New patient visit (15+ min) | 61 | $2,898 | $48 |
| New patient visit (45+ min) | 25 | $2,360 | $94 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 18 | $2,048 | $114 |
| Return visit (30+ min) | 24 | $1,850 | $69 |
| New patient visit (30+ min) | 11 | $730 | $66 |
| Short return visit | 31 | $691 | $22 |
| Sleep study including heart rate, breathing, and sleep time | 13 | $500 | $38 |
| New patient visit (10+ min) | 26 | $445 | $17 |
| Telehealth originating site facility fee | 14 | $288 | $21 |
2019: 5 services
| New patient visit (60+ min) | 29 | $4,163 | $144 |
| Return visit (30+ min) | 36 | $2,554 | $65 |
| Sleep study in sleep lab (6 years or older) | 16 | $1,739 | $109 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 13 | $1,467 | $113 |
| Short return visit (20+ min) | 19 | $860 | $45 |
Medicaid work
$2,742 in 2024
Medicaid paid $2,742 for 14 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 14 | $2,742 |
| 2024 | 14 | 1 | 14 | $2,742 |
| 2023 | 14 | 1 | 14 | $434 |
| 2022 | 38 | 2 | 13 | $931 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 14 | $434 |
2022
| New patient visit (45+ min) | 13 | $536 |
| Return visit (30+ min) | 25 | $394 |
Drugs they prescribed that Part D paid
$164,165
Pharmacies billed $164,165 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 29% of their Part D prescriptions (58 of 201) in 2024. A higher opioid share than 9 in 10 peers; the typical sleep medicine clinician is at 0%. Long-acting opioids: 62% of their opioid prescriptions.
195 generic and fewer than 11 brand-name prescriptions · $164,165 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zolpidem | 27 | $984 | $36 |
| Gabapentin | 25 | $877 | $35 |
| Methadone | 36 | $337 | $9 |
| Clonazepam | 16 | $302 | $19 |
| Armodafinil | 12 | $264 | $22 |
See all 6 drugs
| Zolpidem | 27 | $984 | $36 |
| Gabapentin | 25 | $877 | $35 |
| Methadone | 36 | $337 | $9 |
| Clonazepam | 16 | $302 | $19 |
| Armodafinil | 12 | $264 | $22 |
| Pregabalin | 11 | $146 | $13 |
Year by year
| 2024 | 201 | 31 | 29% (58) | None | $164,165 |
| 2023 | 176 | 36 | 37% (65) | 13% | $257,483 |
| 2022 | 123 | 28 | 22% (27) | 30% | $262,241 |
| 2021 | 40 | 16 | None | 38% | $177,325 |
| 2020 | 45 | 23 | None | None | $3,766 |
| 2019 | 464 | 115 | 6% (28) | None | $465,987 |
| 2018 | 402 | 99 | 3% (12) | 40% | $383,608 |
| 2017 | 210 | 70 | 0% (0) | 32% | $158,822 |
| 2016 | 66 | 33 | None | 20% | $20,179 |
| 2015 | 60 | 16 | 18% (11) | 63% | $191,184 |
| 2014 | 25 | None | 0% (0) | 60% | $71,004 |
| 2013 | 50 | 14 | 0% (0) | 24% | $64,015 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Gabapentin | 33 | $1,480 | $45 |
| Methadone | 50 | $478 | $10 |
| Pregabalin | 14 | $398 | $28 |
| Tramadol | 11 | $21 | $2 |
2022: 4 drugs
| Belsomra | 14 | $7,049 | $503 |
| Pregabalin | 13 | $1,115 | $86 |
| Gabapentin | 16 | $614 | $38 |
| Methadone | 20 | $229 | $11 |
2019: 11 drugs
| Xyrem | 28 | $395,469 | $14,124 |
| Neupro | 15 | $17,114 | $1,141 |
| Zolpidem | 46 | $2,895 | $63 |
| Carbidopa-Levodopa | 29 | $1,883 | $65 |
| Dextroamphetamine Sulfate | 13 | $1,830 | $141 |
| Gabapentin | 45 | $1,002 | $22 |
| Levetiracetam | 17 | $544 | $32 |
| Methylphenidate | 11 | $521 | $47 |
| Methadone | 26 | $423 | $16 |
| Pramipexole Dihydrochloride | 21 | $339 | $16 |
| Trazodone | 21 | $332 | $16 |
2018: 14 drugs
| Xyrem | 25 | $326,974 | $13,079 |
| Neupro | 13 | $11,498 | $884 |
| Modafinil | 19 | $4,407 | $232 |
| Dextroamphetamine Sulfate | 19 | $2,587 | $136 |
| Carbidopa-Levodopa | 21 | $1,376 | $66 |
| Ambien Cr | 12 | $1,338 | $112 |
| Zolpidem | 23 | $1,270 | $55 |
| Temazepam | 13 | $1,171 | $90 |
| Gabapentin | 46 | $934 | $20 |
| Methylphenidate | 14 | $759 | $54 |
| Zolpidem Tartrate Er | 11 | $506 | $46 |
| Eszopiclone | 17 | $394 | $23 |
| Trazodone | 13 | $172 | $13 |
| Ropinirole | 12 | $155 | $13 |
2017: 8 drugs
| Xyrem | 11 | $134,811 | $12,256 |
| Modafinil | 11 | $2,280 | $207 |
| Carbidopa-Levodopa | 16 | $1,207 | $75 |
| Ambien Cr | 12 | $951 | $79 |
| Gabapentin | 25 | $460 | $18 |
| Zolpidem | 23 | $196 | $9 |
| Pramipexole Dihydrochloride | 12 | $152 | $13 |
| Clonazepam | 11 | $99 | $9 |
2013: 1 drug
| Levetiracetam | 15 | $372 | $25 |
Money from drug and device companies
$17,128 in 2025
| 2025 | 3 | 14 | $15,593 | $17,128 |
| 2024 | 2 | 20 | None | $3,943 |
| 2023 | 2 | 5 | $2,500 | $3,426 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | None | $16,984 | 12 payments
|
| Jazz Pharmaceuticals | None | $104 | 1 payment
|
| Avadel CNS Pharmaceuticals | None | $39 | 1 payment
|
See all 14 published payments
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-12-17 | None | $9,843 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-12-17 | None | $58 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-12-17 | None | $59 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-11 | None | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-11 | None | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-11 | None | $43 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-11 | None | $53 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-11 | None | $60 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-10-11 | None | $839 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-10-10 | None | $245 |
| Jazz Pharmaceuticals | Meals · 2025-06-09 | None | $104 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-02-05 | None | $2,875 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-02-05 | None | $2,875 |
| Avadel CNS Pharmaceuticals | Meals · 2025-01-21 | None | $39 |
See earlier years (2024, 2023)
2024: $3,943
| Takeda Pharmaceuticals U.S.A. | None | $3,800 | 18 payments
|
| Jazz Pharmaceuticals | Xywav | $143 | 2 payments
|
2023: $3,426
| Takeda Pharmaceuticals U.S.A. | None | $3,324 | 3 payments
|
| Jazz Pharmaceuticals | Xywav | $102 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Tak-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) · 2023 | Their institution | $58 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972894129
- Licence
- CA A136548California A136548: Current · expires 2027-02-28
- Trained
- University of Texas Southwestern Medical School at Dallas, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084S0012X (2084S0012X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-04-22
- NPI last updated
- 2024-04-30
- NPI record certified
- 2024-04-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St, Redwood City, CA, 94063